drugset / Trial / NCT06029530
Delaying the Onset of Nearsightedness Until Treatment Study
Phase 1
Withdrawn
Ohio State University
Case Western Reserve University · collabIllinois College of Optometry · collabIndiana University · collabNew England College of Optometry · collabPennsylvania College of Optometry · collabSouthern California College of Optometry at Marshall B. Ketchum University · collabSouthern College of Optometry · collabStanford University · collabState University of New York · collabUniversity of California, Berkeley · collabUniversity of Houston · collabUniversity of Missouri, St. Louis · collabUniversity of the Incarnate Word · collab
RandomizedParallel-groupQuadruple-blindOther
Summary
Participants eligible for the study will be randomized to one of three concentrations of atropine and followed for a month.
Timeline
- Start
- 2024-01-01
- Primary completion
- 2024-08-31
- Completion
- 2024-08-31
Outcome
Outcome not reported
Stopped: “sIRB determined feasibility study could not be done because of no benefits of the treatment drops in short time violated FDA requirements”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Atropine | Other / unclassified | 0.01 % | Topical |
| Comparator | Atropine | Other / unclassified | 0.03 % | Topical |
| Comparator | Atropine | Other / unclassified | 0.05 % | Topical |